1. Exact Sciences Q2 Earnings Surpass Expectation, But Analyst Says Stock Has Limited Growth

    By Vandana Singh Exact Sciences Corp (NASDAQ: EXAS ) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the consensus of $599.03 million . Screening revenue was $462.8 million, an increase of 31%. Precision Oncology
  2. Thermo Fisher Below Street Expectation, Lowers Annual Guidance Citing 'Macroeconomic Environment'

    By Vandana Singh Thermo Fisher Scientific Inc (NYSE: TMO) has posted Q2 revenue of $10.69 billion, down 3% Y/Y, missing the consensus of $10.98 billion . Organic revenue was 3% lower, Core organic revenue growth was 2%, and COVID-19 testing revenue was $0.08 billion . Revenue from Lif
  3. Medpace Outperforms Q2 Expectations: Analyst Says High Expectations, Softer Margins Will Likely Temper Enthusiasm

    By Vandana Singh Medpace Holdings Inc (NASDAQ: MEDP ) reported Q2 revenue of $460.9 million, up 31.2%Y/Y, beating the consensus of $433.69 million, representing a backlog conversion rate of 18.7% . Net new business awards were $574.8 million, up 27.6% Y/Y, which resulted in a net boo